Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + Isatuximab in Relapsed/Refractory Multiple Myeloma (ELISA)
NCT06832865Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab, isatuximab in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Started Aug 2025; status: recruiting.
02
Drugs
elranatamabisatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06832865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832865.